BMY
Bristol Myers SquibbBristol Myers Squibb is a pharmaceuticals name in the health care sector. Over the past year it returned +36.4%, against +2.5% over three months and -12.7% over one. It sits just 1.1% above its 200-day average, technically in an uptrend, but without much room. Annualized volatility of 27.1% is moderate by single-stock standards.
Its worst peak-to-trough decline over the year was -12.7%, and it has traded a median $615M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.11 with the S&P 500 proxy, so it has been moving substantially on its own.
How BMY scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.
Start a free 7-day trial| 1 day | -3.8% |
| 1 week | -7.0% |
| 1 month | -12.7% |
| 3 months | +2.5% |
| 6 months | +1.3% |
| 1 year | +36.4% |
| 12-1 momentum | +56.3% |
| Volatility (1y, annualized) | 27.1% |
| Max drawdown (1y) | -12.7% |
| Distance vs 200-day average | +1.1% |
| Return per unit of risk | 1.34 |
| Median daily dollar volume | $615M |
Get BMY when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.